Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Elekta Esprit receives Red Dot design award for its focus on patients and clinicians

Elekta

Elekta’s latest Leksell Gamma Knife® stereotactic radiosurgery (SRS) system, Esprit, wins Red Dot Award

STOCKHOLM – Elekta (EKTA-B.ST) Esprit, a high precision stereotactic radiosurgery device, used to treat targets in the brain, such as tumors, vascular malformations, or functional disorders, has been awarded the Red Dot Award for product design in the medical devices and technology design category. By combining form and function in an exquisite manner, Elekta Esprit has received an internationally renowned winner label of the highest reputation.
 
According to the Red Dot organization, its award represents global recognition of belonging to the best in design and business and the Red Dot Design Award competition has been held since 1955. The jury, comprising some 50 international experts, tests, discusses and evaluates each entry individually.
 
This latest incarnation of the trusted Leksell Gamma Knife offers more efficient and seamless workflows with a modern aesthetic and a clean, light and friendly expression. Moreover, Elekta Esprit emphasizes simple, minimalist design language that shifts the focus away from the machine and celebrates Elekta’s emphasis on the user and patient experience of the system.
 
Susanna Francke Rodau, Senior VP & Head of Neuro Solutions, said: “The experience of the user and the patient is at the heart of this innovation, where design and function have been combined in a holistic, seamlessly integrated package. Although Esprit is technically complex, it is an easy-to-use solution capable of treating very challenging indications and provides life-changing results for patients.”
 
Elekta Esprit offers more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person.
 
For more information, visit www.elekta.com/elekta-esprit
 
Elekta Esprit is CE marked and FDA 510(k) cleared, with limited global availability.
 
 
# # #
 
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com  
Time zone: CET: Central European Time
 
Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
 
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.

Image Attachments


Elekta Esprit Patient In Treatment Position Mask Print

Attachments


Sweden Esprit Red Dot Award 2023 EN

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.